AbbVie said upadacitinib achieved clinical remission and endoscopic response at one year in a Phase 3 maintenance study in patients with Crohn's disease. "AbbVie: Upadacitinib Achieved Clinical Remission at One Year in Crohn's Disease" at 9:08 a.m. ET incorrectly called the drug epadacitinib.

(END) Dow Jones Newswires

May 11, 2022 10:52 ET (14:52 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more AbbVie Charts.